Revvity's EUROIMMUN Launches Solution for Specific Typing of Alzheimer's Disease Associated APOE Gene
02 Ottobre 2024 - 2:00PM
Business Wire
APOE genotyping allows assessment of a
patient’s risk for adverse effects from new anti-amyloid therapy
for Alzheimer’s
Revvity, Inc. (NYSE: RVTY), announced today the launch of the
in-vitro diagnostic EURORealTimeTM APOE assay in European countries
that accept the CE mark, which will enable accurate genotyping of
the APOE gene. APOE genotyping is valuable to assess a patient’s
risk for side effects prior to the start of an anti-amyloid (beta)
therapy in Alzheimer’s disease.
“With the introduction of new disease-modifying drugs for
treating Alzheimer’s, a new era of therapy has begun for this
incurable disease. However, it has been found that patients taking
these treatments with a certain form of the APOE gene have a
significant risk for developing potentially life-threatening side
effects, called ARIA, referring to edema or microbleedings in the
brain,” explains Dr. Lars Komorowski, chief scientific officer of
EUROIMMUN. “Being able to easily determine the APOE genotype of
patients before starting therapy is key to assessing the individual
risk for potential negative consequences.”
The real-time EURORealTime APOE PCR test allows simultaneous
detection of the three most frequent APOE forms, designated E2, E3
and E4. Carriers of exclusively E4 exhibit the highest risk for
ARIA under therapy. With the new test now available from Revvity’s
EUROIMMUN, only one reaction is required using genomic DNA isolated
from a single blood sample to determine the patient’s APOE
genotype. The assay processing can be automated to scalable degrees
on Revvity instruments, including the EUROIMMUN PreNAT IITM and the
chemagic™ 360 platforms. Results are evaluated, documented and
archived using the EURORealTime analysis software.
For clinicians treating Alzheimer’s patients, this approach to
APOE genotyping will grant additional patient information and will
enable a more personalized approach in anti-amyloid (beta)
treatment.
About Revvity
At Revvity, “impossible” is inspiration, and “can’t be done” is
a call to action. Revvity provides health science solutions,
technologies, expertise and services that deliver complete
workflows from discovery to development, and diagnosis to cure.
Revvity is revolutionizing what’s possible in healthcare, with
specialized focus areas in translational multi-omics technologies,
biomarker identification, imaging, prediction, screening, detection
and diagnosis, informatics and more.
With 2023 revenue of more than $2.7 billion and over 11,000
employees, Revvity serves customers across pharmaceutical and
biotech, diagnostic labs, academia and governments. It is part of
the S&P 500 index and has customers in more than 190
countries.
Stay updated by following our Newsroom, LinkedIn, X, YouTube,
Facebook and Instagram.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241002635590/en/
Media Relations: Chet Murray (781) 462-5126
chet.murray@revvity.com Investor Relations: Steve Willoughby
steve.willoughby@revvity.com
Grafico Azioni Revvity (NYSE:RVTY)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Revvity (NYSE:RVTY)
Storico
Da Dic 2023 a Dic 2024
